Edgewise Therapeutics (EWTX) Accumulated Depreciation (2020 - 2026)

Edgewise Therapeutics has disclosed Accumulated Depreciation across 7 years of filings, most recently posting $7.3 million for Q1 2026.

• Accumulated Depreciation for Q1 2026 came in at $7.3 million, up 40.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.3 million (up 40.55% YoY), and the FY2025 annual result was $6.8 million, up 44.48% from the prior year.
• Accumulated Depreciation came in at $7.3 million for Q1 2026 at Edgewise Therapeutics, up from $6.8 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $7.3 million in Q1 2026 to a low of $785000.0 in Q1 2022.
• The 5-year median for Accumulated Depreciation is $3.1 million (2024), against an average of $3.4 million.
• Across the five-year window, Accumulated Depreciation jumped 145.63% in 2023 and soared 40.55% in 2026, its largest moves.
• Edgewise Therapeutics' Accumulated Depreciation stood at $1.1 million in 2022, then surged by 145.63% to $2.6 million in 2023, then jumped by 79.09% to $4.7 million in 2024, then jumped by 44.48% to $6.8 million in 2025, then gained by 7.93% to $7.3 million in 2026.
• The last three Accumulated Depreciation figures came in at $7.3 million (Q1 2026), $6.8 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.